Premium
The effects of orlistat and fenofibrate, alone or in combination, on high‐density lipoprotein subfractions and pre‐beta1‐HDL levels in obese patients with metabolic syndrome
Author(s) -
Filippatos T. D.,
Liberopoulos E. N.,
Kostapanos M.,
Gazi I. F.,
Papavasiliou E. C.,
Kiortsis D. N.,
Tselepis A. D.,
Elisaf M. S.
Publication year - 2008
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2007.00733.x
Subject(s) - fenofibrate , orlistat , medicine , endocrinology , metabolic syndrome , overweight , high density lipoprotein , lipoprotein , cholesterol , obesity , weight loss
Objective: We assessed the effect of orlistat and fenofibrate, alone or in combination, on plasma high‐density lipoprotein (HDL) subfractions and plasma pre‐beta1‐HDL levels in overweight and obese subjects with metabolic syndrome (MetS). Methods: Patients (n = 89) were prescribed a low‐fat low‐calorie diet and were randomly allocated to receive orlistat 120 mg three times daily (O group), micronized fenofibrate 200 mg/day (F group) or both (OF group) for 6 months. HDL subfractions were determined using a polyacrylamide gel tube electrophoresis method and pre‐beta1‐HDL levels using enzyme‐linked immunoabsorbent assay. Results: We observed a significant change of high‐density lipoprotein cholesterol (HDL‐C) levels only in the F group (+3%, p < 0.05). Large HDL‐C levels were significantly increased and small HDL‐C levels were significantly reduced with O administration. In F group we observed a significant increase of small HDL‐C levels. No significant change of large or small HDL‐C levels was observed with combination treatment. We observed a significant increase of pre‐beta1‐HDL levels in all groups, which was significantly greater in OF group compared with O or F monotherapy. Conclusion: OF combination increased the antiatherogenic pre‐beta1‐HDL levels in overweight and obese patients with MetS. Furthermore, OF combination counterbalanced the reduction of small HDL‐C levels observed with orlistat monotherapy.